ClinicalTrials.gg
CompletedNCT05136170PROTEGO-2Updated Nov 26, 2025Results posted

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

A Phase 3 interventional study of Cenegermin and Vehicle in Dry Eye Disease, sponsored by Dompé Farmaceutici S.p.A. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Dompé Farmaceutici S.p.A · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Dompé Farmaceutici S.p.A.

Started
2022
with 1 other
Phase 3
2 of 10
none open now
Registered
6th of 10
by date

Among the 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A, this one is one of 2 that started in 2022, is one of 2 in phase 3, and was the 6th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A, or all of them as a file.
02

Study summary

Primary Objectives:

  • To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) > 10 mm/5 min at Week 4 by testing the superiority.
  • To compare the efficacy of cenegermin vs vehicle in Symptom Assessment in Dry Eye questionnaire (SANDE) global score at Week 12 by testing the superiority.

Secondary Objectives:

  • To compare the efficacy of cenegermin vs vehicle in Schirmer I test at Week 4, 8, 12 and 16 by testing the superiority.
  • To compare the efficacy of cenegermin vs vehicle in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) at Week 4, 8, 12 and 16 by testing the superiority.
  • To compare the efficacy of cenegermin vs vehicle in Tear Film Break-Up Time (TFBUT) at Week 4, 8, 12 and 16 by testing the superiority.
  • To compare the efficacy of cenegermin vs vehicle in SANDE scores at Week 8, 12 and 16 by testing the superiority.
  • To compare the efficacy of cenegermin vs vehicle in worsening in symptom scores (SANDE) and/or NEI score at Week 4 by testing the superiority.
  • To compare the efficacy of cenegermin vs vehicle in impact of dry eye on everyday life (IDEEL) questionnaire at Week 4, 8, 12 and 16 by testing the superiority.
Read the detailed description

This was a 4 week phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of cenegermin ophthalmic solution at 20 mcg/mL solution versus vehicle, in patients with severe Sjogren's dry eye disease under treatment with Ciclosporine A (or other drugs of the same class).

During the Screening all procedures for inclusion and exclusion were performed. From the day of screening, the patients stopped any kind of further treatment, except CsA and commercially available preservative-free artificial tears provided by the Sponsor for a period of 8 days and 10 days as maximum. At the end of the washout period, patients still meeting the entry criteria for this study were randomized 1:1 and treated for 4 weeks with either cenegermin ophthalmic solution 20 mcg/mL three times a day (TID) or vehicle TID.

In addition to topical CsA eye drops (both groups continued with topical CsA eye drops, or other topical ophthalmic treatment of the same class), during the 4 weeks of masked treatment, only the administration of investigational medicinal product (IMP) was allowed.

During the follow up period, the patient could administer additional preservative-free artificial tear eye drops, provided by the Sponsor, only if strictly needed, and had to document in the patient's Diary the number of additional drops administered for each eye.

Patients were then followed-up for efficacy and safety endpoints until Week 16 and for safety endpoints until Week 24.

The total duration of the study was 25 weeks including 1 week of screening.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

Keywords

  • Sjogren's dry eye
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥ 18 years.
  2. Patients with a confirmed diagnosis of Sjögren's syndrome or other disease known to induce Sjögren's DED.
  3. Patients with severe Sjögren's DED characterized by the following clinical features:

    1. Corneal and/or conjunctival staining with fluorescein using National Eye Institute (NEI) grading system ≥ 3.
    2. SANDE questionnaire >25 mm.
    3. Schirmer test I (without anaesthesia) ≥ 2 ≤ 5 mm/5 min.
  4. The same eye (eligible eye) must fulfil all the above criteria.
  5. Patients diagnosed with severe Sjögren's DED at least 3 months before enrolment (current use or recommended use of artificial tears for the treatment of Sjögren's related DE).
  6. Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units (20/200 Snellen value) in each eye at the time of study enrolment.
  7. If a female of , have a negative urine pregnancy test and use a highly effective method to avoid pregnancy for the duration of the trial and 30 days after the study treatment period. Males of should use effective during treatment and 30 days after the study treatment period.
  8. Patients who have given written before any study-related procedures not part of standard medical care are performed.
  9. Patients must have the ability and willingness to comply with study procedures.
  10. Patients under treatment with topical cyclosporine (CsA), or topical ophthalmic treatments of the same class for at least 30 days before Screening Visit (Day -8).

Exclusion criteria

Exclusion Criteria:

  1. Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written , and to allow the completion of all study assessments.
  2. Evidence of an active ocular infection, in either eye.
  3. Presence of any other ocular disorder or condition requiring topical medication during the entire duration of study in either eye.
  4. History of severe systemic allergy or of ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis and/or keratitis other than dry eye.
  5. Intraocular inflammation defined as Tyndall score > 0.
  6. History of in the last 5 years.
  7. Systemic disease not stabilized within 1 month before Screening Visit (e.g., diabetes with glycemia out of range, thyroid malfunction) or judged by the Investigator to be incompatible with the study (e.g., current systemic infections) or with a condition incompatible with the frequent assessment required by the study.
  8. Patient had a serious adverse reaction or significant to any drug or chemically related compounds or had a allergy to drugs, foods, amide local anaesthetics or other materials including commercial artificial tears (in the opinion of the Investigator).
  9. Females of (those who are not surgically sterilized or for at least 1 year) were excluded from participation in the study if they met any one of the following conditions:

    1. were currently pregnant or,
    2. had a positive result at the urine pregnancy test (Baseline/Day 1) or,
    3. intended to become pregnant during the study treatment period or,
    4. were breast-feeding or,
    5. were not willing to use highly effective measures, such as: combined (oestrogen and progesterone containing) hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, implantable, injectable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner, sexual abstinence - during the entire course of and 30 days after the study treatment period.
  10. Any concurrent medical condition, that in the judgment of the PI, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being.
  11. Use of topical , lifitegrast, autologous serum tears in either eye during the study (previous use not an exclusion criteria but must be discontinued at the Screening Visit).
  12. Contact lenses, True Tear device, moisture goggles, sutureless amniotic membrane or punctum plug use during the study (previous use not an exclusion criteria but must be discontinued at the Screening Visit).
  13. History of drug addiction or alcohol abuse in the last 2 years.
  14. Any prior ocular surgery (including refractive, palpebral and cataract surgery) if within 90 days before the Screening Visit.
  15. Participation in a clinical trial with a new active substance during the past 3 months.
  16. Participation in another clinical trial study at the same time as the present study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Cenegermin

    One drop of cenegermin 20 mcg/mL (rhNGF 20 mcg/mL), in the pharmaceutical form of ophthalmic sterile solution, was instilled in both eyes three times daily (TID), every six hours.

    Drug: Cenegermin

  • Placebo comparator
    Vehicle

    In this arm one drop of vehicle was instilled in both eyes TID for 28 consecutive days.

    Other: Vehicle

Interventions

  • Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.

    Also known as: Oxervate®

  • OtherVehicle

    Vehicle was instilled with the same scheme of the test product

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4

    The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer's test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye. No units other than participants were assigned.

    Time frame: At Week 4 (Visit 3)

  2. Change From Baseline in Symptom Questionnaire (SANDE) Global Score at Week 12

    SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).

    Time frame: At Week 12 (Visit 5 - Follow up)

Secondary outcomes

  1. Key Secondary Outcome: Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min at Week 8

    The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye. No units other than participants were assigned.

    Time frame: At Week 8 (Visit 4)

  2. Key Secondary Outcome: Change From Baseline in Symptom Assessment in Dry Eye Questionnaire (SANDE) Score for Severity at Week 12

    The Symptom Assessment in Dry Eye (SANDE) questionnaire was a short questionnaire to evaluate both dry eye intensity/severity and frequency. This questionnaire used a 100 mm horizontal line (Visual Analogue Scale - VAS) for each of the 2 questions to assess ocular discomfort and/or dryness experienced by the patients. In the SANDE questionnaire, frequency of symptoms ranges from "rarely" to "all of the time" and the severity of symptoms ranged from "very mild" to "very severe". Patients were asked to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE scale ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). In this outcome severity score at week 12 was assessed.

    Time frame: At Week 12 (Visit 5 - Follow-up)

  3. Key Secondary Outcome: Change From Baseline in Symptoms Assessment in Dry Eye Questionnaire (SANDE) Score for Frequency at Week 12

    SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale, VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).

    Time frame: At Week 12 (Visit 5 - Follow-up)

  4. Key Secondary Outcome: Change From Baseline in "Quality of Life, Dry Eye Treatment Satisfaction & Bother and Dry Eye Symptom-Bother" Modules Measured by "Impact of Dry Eye on Everyday Life [IDEEL]" Questionnaire at Week 12 and at Week 4.

    IDEEL was a 57-item questionnaire that assessed the impact of dry eye symptoms on everyday life. It consisted of 3 modules: * Dry eye Quality of Life (27 items) composed by 3 dimensions: 1. Impact on Daily Activities 2. Emotional Impact 3. Impact on Work Scores for each dimension of this module ranged from 0 to 100, where higher scores indicated less impact on daily activities, on work and emotions. * Treatment Satisfaction \& Bother (8 items) composed by 2 dimensions: 1. Satisfaction with Treatment Effectiveness 2. Treatment-Related Bother / Inconvenience Scores for each dimension of this module range from 0 to 100, where higher scores indicate greater satisfaction with treatment effectiveness and less treatment-related bother. * Symptom Bother (20 items) composed by 1 dimension: 1. Dry Eye Symptom-Bother Scores for the dimension of this module ranged from 0 to 100, where higher scores indicated a greater symptom bother. No combination of dimensions scores was done.

    Time frame: At Week 12 (Visit 5 - Follow-up) and Week 4 (Visit 3)

  5. Key Secondary Outcome: Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 4, Week 8 and Week 12

    Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological. Hence, the shorter the time, the worse the outcome.

    Time frame: At week 4 (Visit 3) , Week 8 (Visit 4), and Week 12 (Visit 5 - Follow-up)

  6. Change From Baseline in Schirmer I Test (Without Anaesthesia) at Week 4, Week 8, Week 12, and Week 16

    The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.

    Time frame: At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)

  7. Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 4, Week 8, Week 12 and Week 16

    The NEI/Industry Workshop guidelines were used for grading the scale of corneal and conjunctival damage. The cornea was divided into five sectors (central, superior, inferior, nasal and temporal), each of which was scored on a scale of 0-3, with a maximal total corneal staining score of 15. Both nasally and temporally, the conjunctiva was divided into a superior paralimbal area, an inferior paralimbal area, and a peripheral area with a grading scale of 0-3 and with a maximal total score of 9 for the nasal and temporal conjunctiva (overall the total score ranged from 0-18). Briefly, grade 0 reflected normal/healthy situation, whereas grade 3 reflected a severe damage in the considered sector.

    Time frame: At Week 4 (Visit 3), Week 8 (Visit 4) , Week 12 (Visit 5) and Week 16 (Visit 6)

  8. Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 4, Week 8, Week 12 and Week 16

    Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological. The shorter the time, the worse the outcome.

    Time frame: At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)

  9. Change From Baseline in Symptoms Questionnaire (SANDE) Global Scores, and for Severity and Frequency at Week 8, Week 12, and Week 16

    SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).

    Time frame: At Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)

  10. Number of Patients Experienced a Worsening in Symptom Scores (SANDE Global Scores) and/or NEI Score ≥ 50% at Week 4

    Symptoms Scores (SANDE) and/or NEI Score were punctually described in the previous outcome descriptions. For Sande score, the scale ranges from 0 to 100 for both severity and frequency, where 0 was the best condition and 100 marked the worst condition. Hence the higher the score, the worse the outcome. For NEI score, the maximum score (worst outcome) was 15, and the minimum (best outcome) was 0; hence the higher the score, the worse the outcome. Please note that mean is an adjusted mean.

    Time frame: At Week 4 (Visit 3)

  11. Change From Baseline in "Quality of Life, Dry Eye Treatment Satisfaction & Bother and Dry Eye Symptom-Bother" Modules Measured by "Impact of Dry Eye on Everyday Life [IDEEL]" Questionnaire at Week 4, Week, 8, Week 12, and Week 16

    IDEEL was a 57-item questionnaire that assessed the impact of dry eye symptoms on everyday life. It consisted of 3 modules: * Dry eye Quality of Life (27 items) composed by 3 dimensions: 1. Impact on Daily Activities 2. Emotional Impact 3. Impact on Work Scores for each dimension of this module ranged from 0 to 100, where higher scores indicated less impact on daily activities, on work and emotions. * Treatment Satisfaction \& Bother (8 items) composed by 2 dimensions: 1. Satisfaction with Treatment Effectiveness 2. Treatment-Related Bother / Inconvenience Scores for each dimension of this module range from 0 to 100, where higher scores indicate greater satisfaction with treatment effectiveness and less treatment-related bother. * Symptom Bother (20 items) composed by 1 dimension: 1. Dry Eye Symptom-Bother. Scores for the dimension of this module ranged from 0 to 100, where higher scores indicated greater symptom bother. No combination of dimensions scores was done.

    Time frame: At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)

Other outcomes

  1. Number of Patients With at Least One Treatment-emergent Adverse Event (TEAE) From Screening Day to Week 24

    Treatment emergent adverse events (TEAEs) were undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment.

    Time frame: From Screening day (Day -8) up to Week 24 (Visit 7 - Follow-up)

  2. Use of Preservative Free Artificial Tears Use (Number of Drops/Day).

    Use of Preservative Free Artificial Tears by Study Period is calculated as: total number of drops of the preservative free artificial tears during the X period/ total number of days of the X period \* 100.

    Time frame: Treatment period (Day 1 to Week 4), Follow-up period (Week 4 to Week 24), Overall period (Day 1 to Week 24)

  3. Change From Baseline in Schirmer I Test (Without Anaesthesia) at Week 2

    The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.

    Time frame: At week 2 (Visit 2)

  4. Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 2

    The NEI/Industry Workshop guidelines were used for grading the scale of corneal and conjunctival damage. The cornea was divided into five sectors (central, superior, inferior, nasal and temporal), each of which was scored on a scale of 0-3, with a maximal total corneal staining score of 15. Both nasally and temporally, the conjunctiva was divided into a superior paralimbal area, an inferior paralimbal area, and a peripheral area with a grading scale of 0-3 and with a maximal total score of 9 for the nasal and temporal conjunctiva (overall the total score ranged from 0-18). Briefly, grade 0 reflected normal/healthy situation, whereas grade 3 reflected a severe damage in the considered sector.

    Time frame: At Week 2 (Visit 2)

  5. Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 2

    Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological.

    Time frame: At Week 2 (Visit 2)

  6. Change From Baseline in Symptoms Questionnaire (SANDE) Global Scores, and for Severity and Frequency at Week 2, and Week 4

    SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).

    Time frame: At Week 2 (Visit 2) and Week 4 (Visit 3)

  7. Number of Patients Experienced a Worsening in Symptom Scores (SANDE Global Score) and/or NEI Score ≥ 50% Assessed at Week 2

    Symptoms Scores (SANDE) and/or NEI Score were punctually described in the previous outcome descriptions. For Sande score, the scale ranges from 0 to 100 for both severity and frequency, where 0 was the best condition and 100 marked the worst condition. Hence the higher the score, the worse the outcome. For NEI score, the maximum score (worst outcome) was 15, and the minimum (best outcome) was 0; hence the higher the score, the worse the outcome.

    Time frame: At Week 2 (Visit 2)

  8. Change From Baseline in Schirmer Test II (With Topical Anaesthesia) at Week 4

    Schirmer Test II (with anaesthetic) measured baseline plus reflex secretion. The Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.

    Time frame: At Week 4 (Visit 3)

  9. Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA)

    Best corrected visual acuity (BCDVA) was determined by careful refraction according to the standard protocol for refraction. Chart 1 was used for testing the VA of the right eye; Chart 2 for the left eye; and Chart R for refraction only. Retroilluminated standard Early Treatment of Diabetic Retinopathy Study (ETDRS) charts were used. They had 5 Sloan letters on each line of equal difficulty, and there was a geometric progression in letter size from line to line. VAS awarded one point for every letter correctly guessed. A distance of 4 meters was required between the subject's eyes and the VA chart. When a subject cannot read at least 20 letters on the chart at 4 meters, the subject was tested at 1 meter. If 20 or more letters were read at 4 meters, the VAS for that eye was recorded as the number of letters correct at 4 meters plus 30. Otherwise, the VAS was the number of letters read correctly at 1 meter plus the number read at 4 meters. The higher the score the better the outcome.

    Time frame: At Week 2 (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)

07

Results

Posted Dec 4, 2024

Participant flow

Three sites in Italy out of the four opened, and 7 sites in US enrolled patients. A total of 97 adult patients (≥ 18 years) with a diagnosis of severe Sjögren's DED was assessed for eligibility. There were 12 screening failures. The remaining patients (n=85) were randomized 1:1 as follows: 44 to cenegermin and 41 to vehicle. One patient in the vehicle group did not receive study medication and was excluded from the SAF and FAS.

Participant flow — Overall Study
MilestoneCenegerminVehicle
Started4441
Randomized but not treated01
Safety population (saf)4440
Full analysis set population (fas)4440
Per protocol set (pp)3833
Completed4139
Not completed32
Withdrew: Withdrawal by subject22
Withdrew: Can no longer make office visits10

Outcome measures

PrimaryNumber of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4

The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer's test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye. No units other than participants were assigned.

Time frame:
At Week 4 (Visit 3)
Reported as:
Count of participants · Participants
Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4
ParticipantsCenegermin - FASVehicle - FAS
Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4194
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Regression, Logistic · p = 0.002 (P-value of treatment variable from logistic regression model on proportion of patients reaching a value of Schirmer I test (without anesthesia) \>10mm/5min) · Odds ratio (or): 8.498 · 95% CI 2.165 to 33.356
PrimaryChange From Baseline in Symptom Questionnaire (SANDE) Global Score at Week 12

SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).

Time frame:
At Week 12 (Visit 5 - Follow up)
Reported as:
Mean · score on a scale
Change From Baseline in Symptom Questionnaire (SANDE) Global Score at Week 12
score on a scaleCenegermin - FASVehicle - FAS
Change From Baseline in Symptom Questionnaire (SANDE) Global Score at Week 12-12.452 (-19.962 to -4.942)-13.042 (-20.650 to -5.433)
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · ANCOVA · p = 0.890 (P-value of adjusted means difference between treatments from the ANCOVA model on change from baseline in the global SANDE score.) · Adjusted means difference: 0.59 · 95% CI -7.801 to 8.981
SecondaryKey Secondary Outcome: Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min at Week 8

The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye. No units other than participants were assigned.

Time frame:
At Week 8 (Visit 4)
Reported as:
Count of participants · Participants
Key Secondary Outcome: Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min at Week 8
ParticipantsCenegermin - FASVehicle - FAS
Key Secondary Outcome: Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min at Week 8112
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Regression, Logistic · p = 0.022 · Odds ratio (or): 6.648 · 95% CI 1.307 to 33.808
SecondaryKey Secondary Outcome: Change From Baseline in Symptom Assessment in Dry Eye Questionnaire (SANDE) Score for Severity at Week 12

The Symptom Assessment in Dry Eye (SANDE) questionnaire was a short questionnaire to evaluate both dry eye intensity/severity and frequency. This questionnaire used a 100 mm horizontal line (Visual Analogue Scale - VAS) for each of the 2 questions to assess ocular discomfort and/or dryness experienced by the patients. In the SANDE questionnaire, frequency of symptoms ranges from "rarely" to "all of the time" and the severity of symptoms ranged from "very mild" to "very severe". Patients were asked to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE scale ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). In this outcome severity score at week 12 was assessed.

Time frame:
At Week 12 (Visit 5 - Follow-up)
Reported as:
Mean · score on a scale
Key Secondary Outcome: Change From Baseline in Symptom Assessment in Dry Eye Questionnaire (SANDE) Score for Severity at Week 12
score on a scaleCenegermin - FASVehicle - FAS
Key Secondary Outcome: Change From Baseline in Symptom Assessment in Dry Eye Questionnaire (SANDE) Score for Severity at Week 12-11.851 (-19.824 to -3.878)-12.072 (-20.188 to -3.957)
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · ANCOVA · p = 0.962 (P-value of adjusted means difference between treatments from the ANCOVA model on change from baseline in SANDE score for severity at Week 12.) · Adjusted means difference: 0.221 · 95% CI -8.934 to 9.377
SecondaryKey Secondary Outcome: Change From Baseline in Symptoms Assessment in Dry Eye Questionnaire (SANDE) Score for Frequency at Week 12

SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale, VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).

Time frame:
At Week 12 (Visit 5 - Follow-up)
Reported as:
Mean · score on a scale
Key Secondary Outcome: Change From Baseline in Symptoms Assessment in Dry Eye Questionnaire (SANDE) Score for Frequency at Week 12
score on a scaleCenegermin - FASVehicle - FAS
Key Secondary Outcome: Change From Baseline in Symptoms Assessment in Dry Eye Questionnaire (SANDE) Score for Frequency at Week 12-14.606 (-23.007 to -6.204)-14.770 (-23.258 to -6.281)
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · ANCOVA · p = 0.973 (P-value of adjusted means difference between treatments from the ANCOVA model on change from baseline in SANDE score for frequency at Week 12.) · Adjusted means difference: 0.164 · 95% CI -9.221 to 9.549
SecondaryKey Secondary Outcome: Change From Baseline in "Quality of Life, Dry Eye Treatment Satisfaction & Bother and Dry Eye Symptom-Bother" Modules Measured by "Impact of Dry Eye on Everyday Life [IDEEL]" Questionnaire at Week 12 and at Week 4.

IDEEL was a 57-item questionnaire that assessed the impact of dry eye symptoms on everyday life. It consisted of 3 modules: * Dry eye Quality of Life (27 items) composed by 3 dimensions: 1. Impact on Daily Activities 2. Emotional Impact 3. Impact on Work Scores for each dimension of this module ranged from 0 to 100, where higher scores indicated less impact on daily activities, on work and emotions. * Treatment Satisfaction \& Bother (8 items) composed by 2 dimensions: 1. Satisfaction with Treatment Effectiveness 2. Treatment-Related Bother / Inconvenience Scores for each dimension of this module range from 0 to 100, where higher scores indicate greater satisfaction with treatment effectiveness and less treatment-related bother. * Symptom Bother (20 items) composed by 1 dimension: 1. Dry Eye Symptom-Bother Scores for the dimension of this module ranged from 0 to 100, where higher scores indicated a greater symptom bother. No combination of dimensions scores was done.

Time frame:
At Week 12 (Visit 5 - Follow-up) and Week 4 (Visit 3)
Reported as:
Least squares mean · score on a scale
Key Secondary Outcome: Change From Baseline in "Quality of Life, Dry Eye Treatment Satisfaction & Bother and Dry Eye Symptom-Bother" Modules Measured by "Impact of Dry Eye on Everyday Life [IDEEL]" Questionnaire at Week 12 and at Week 4.
score on a scaleCenegermin - FASVehicle - FAS
QoL (Daily activities) - Week 413.690 (8.034 to 19.346)11.312 (5.393 to 17.231)
QoL (Daily activities) - Week 1213.769 (7.711 to 19.827)6.659 (0.549 to 12.769)
QoL (Feelings) - Week 48.811 (2.356 to 15.266)12.977 (6.263 to 19.692)
QoL (Feelings) - Week 1211.413 (5.058 to 17.767)10.355 (3.923 to 16.787)
QoL (Work) - Week 410.689 (2.183 to 19.195)14.596 (5.224 to 23.967)
QoL (Work) - Week 1213.225 (5.547 to 20.903)13.509 (5.084 to 21.934)
Treatment Satisfaction (TS) (Treatment - in general) - Week 48.708 (2.786 to 14.630)8.757 (2.493 to 15.022)
TS (Treatment - in general) - Week 127.281 (1.570 to 12.992)5.305 (-0.513 to 11.124)
Symptom-Bother - Week 4-8.030 (-13.302 to -2.758)-13.262 (-18.758 to -7.766)
Symptom-Bother - Week 12-10.814 (-16.220 to -5.407)-10.657 (-16.102 to -5.212)
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.52 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL Quality of Life Module (Daily Activities) at Week 4) · Ls means difference: 2.378 · 95% CI -4.869 to 9.625
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.073 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL Quality of Life Module (Daily Activities) at Week 12.) · Ls means difference: 7.11 · 95% CI -0.653 to 14.873
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.317 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL Quality of Life Module (Feelings) at Week 4.) · Ls means difference: -4.166 · 95% CI -12.322 to 3.989
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.792 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL Quality of Life Module (Feelings) at Week 12.) · Ls means difference: 1.058 · 95% CI -6.786 to 8.901
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.488 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL Quality of Life Module (Work) at Week 4.) · Ls means difference: -3.907 · 95% CI -14.948 to 7.135
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.954 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL Quality of Life Module (Work) at Week 12.) · Ls means difference: -0.284 · 95% CI -9.998 to 9.431
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.99 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL DE Treatment Satisfaction \& Bother module (Satisfaction with Treatment Effectiveness) at Week 4.) · Ls means difference: -0.049 · 95% CI -7.658 to 7.559
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.582 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL DE Treatment Satisfaction \& Bother module (Satisfaction with Treatment Effectiveness) at Week 12.) · Ls means difference: 1.976 · 95% CI -5.065 to 9.017
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.125 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL DE Symptom Bother Module at Week 4.) · Ls means difference: 5.232 · 95% CI -1.457 to 11.922
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.964 (P-value of LS means difference between treatments from the MMRM on change from baseline in IDEEL DE Symptom Bother Module at Week 12.) · Ls means difference: -0.156 · 95% CI -6.912 to 6.6
SecondaryKey Secondary Outcome: Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 4, Week 8 and Week 12

Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological. Hence, the shorter the time, the worse the outcome.

Time frame:
At week 4 (Visit 3) , Week 8 (Visit 4), and Week 12 (Visit 5 - Follow-up)
Reported as:
Least squares mean · seconds
Key Secondary Outcome: Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 4, Week 8 and Week 12
secondsCenegermin - FASVehicle - FAS
Week 41.020 (0.253 to 1.787)0.225 (-0.586 to 1.036)
Week 80.899 (0.074 to 1.725)0.951 (0.088 to 1.813)
Week 120.917 (0.123 to 1.711)0.782 (-0.040 to 1.603)
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.102 (P-value of LS means difference between treatments from the MMRM on change from baseline at Week 4.) · Ls means difference: 0.795 · 95% CI -0.157 to 1.748
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.923 (P-value of LS means difference between treatments from the MMRM on change from baseline at Week 8.) · Ls means difference: -0.051 · 95% CI -1.094 to 0.991
  • Cenegermin - FAS vs Vehicle - FAS · Mixed Model for Repeated Measures · p = 0.787 (P-value of LS means difference between treatments from the MMRM on change from baseline at Week 12) · Ls means difference: 0.136 · 95% CI -0.849 to 1.12
SecondaryChange From Baseline in Schirmer I Test (Without Anaesthesia) at Week 4, Week 8, Week 12, and Week 16

The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.

Time frame:
At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Reported as:
Mean · millimeters
Change From Baseline in Schirmer I Test (Without Anaesthesia) at Week 4, Week 8, Week 12, and Week 16
millimetersCenegermin - FASVehicle - FAS
Week 45.4 ± 5.21.7 ± 3.2
Week 84.9 ± 4.51.5 ± 3.0
Week 124.1 ± 4.73.1 ± 6.3
Week 163.4 ± 4.02.4 ± 4.9
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.014 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.095 (Not statistically significant result. p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
SecondaryChange From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 4, Week 8, Week 12 and Week 16

The NEI/Industry Workshop guidelines were used for grading the scale of corneal and conjunctival damage. The cornea was divided into five sectors (central, superior, inferior, nasal and temporal), each of which was scored on a scale of 0-3, with a maximal total corneal staining score of 15. Both nasally and temporally, the conjunctiva was divided into a superior paralimbal area, an inferior paralimbal area, and a peripheral area with a grading scale of 0-3 and with a maximal total score of 9 for the nasal and temporal conjunctiva (overall the total score ranged from 0-18). Briefly, grade 0 reflected normal/healthy situation, whereas grade 3 reflected a severe damage in the considered sector.

Time frame:
At Week 4 (Visit 3), Week 8 (Visit 4) , Week 12 (Visit 5) and Week 16 (Visit 6)
Reported as:
Mean · score on a scale
Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 4, Week 8, Week 12 and Week 16
score on a scaleCenegermin - FASVehicle - FAS
corneal and conjunctival damage - Week 4-3.6 ± 4.6-2.4 ± 4.7
corneal and conjunctival damage - Week 8-3.1 ± 3.8-2.9 ± 3.9
corneal and conjunctival damage - Week 12-3.4 ± 4.6-3.0 ± 3.8
corneal and conjunctival damage - Week 16-2.0 ± 6.9-2.3 ± 4.2
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.02 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.328 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.287 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.777 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
SecondaryChange From Baseline in Tear Film Break-Up Time (TFBUT) at Week 4, Week 8, Week 12 and Week 16

Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological. The shorter the time, the worse the outcome.

Time frame:
At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Reported as:
Mean · seconds
Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 4, Week 8, Week 12 and Week 16
secondsCenegermin - FASVehicle - FAS
Week 41.1 ± 2.40.2 ± 2.2
Week 80.9 ± 2.50.9 ± 2.3
Week 121.0 ± 2.60.7 ± 1.8
Week 161.3 ± 2.81.1 ± 2.5
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.126 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.968 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.613 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.805 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
SecondaryChange From Baseline in Symptoms Questionnaire (SANDE) Global Scores, and for Severity and Frequency at Week 8, Week 12, and Week 16

SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).

Time frame:
At Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Reported as:
Mean · score on a scale
Change From Baseline in Symptoms Questionnaire (SANDE) Global Scores, and for Severity and Frequency at Week 8, Week 12, and Week 16
score on a scaleCenegermin - FASVehicle - FAS
Global Score - Week 8-12.9 ± 19.0-10.3 ± 19.2
Global Score - Week 12-9.5 ± 17.0-11.3 ± 22.5
Global Score - Week 16-9.0 ± 22.3-11.1 ± 19.0
Severity - Week 8-10.7 ± 19.6-9.9 ± 20.9
Severity - Week 12-8.6 ± 19.6-10.2 ± 25.1
Severity - Week 16-7.9 ± 22.9-10.2 ± 20.2
Frequency - Week 8-16.4 ± 23.2-10.9 ± 21.2
Frequency - Week 12-10.3 ± 23.6-12.3 ± 23.5
Frequency - Week 16-10.5 ± 24.2-12.2 ± 18.6
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.543 (p-value corresponds to two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.677 (p-value corresponds to two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.914 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.874 (p-value corresponds to two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.945 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.727 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.342 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.821 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.926 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
SecondaryNumber of Patients Experienced a Worsening in Symptom Scores (SANDE Global Scores) and/or NEI Score ≥ 50% at Week 4

Symptoms Scores (SANDE) and/or NEI Score were punctually described in the previous outcome descriptions. For Sande score, the scale ranges from 0 to 100 for both severity and frequency, where 0 was the best condition and 100 marked the worst condition. Hence the higher the score, the worse the outcome. For NEI score, the maximum score (worst outcome) was 15, and the minimum (best outcome) was 0; hence the higher the score, the worse the outcome. Please note that mean is an adjusted mean.

Time frame:
At Week 4 (Visit 3)
Reported as:
Count of participants · Participants
Number of Patients Experienced a Worsening in Symptom Scores (SANDE Global Scores) and/or NEI Score ≥ 50% at Week 4
ParticipantsCenegermin - FASVehicle - FAS
Worsening in symptom scores (SANDE global score)145
NEI score >= 50%11
Worsening in symptom scores and/or NEI score >= 50155
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Chi-squared · p = 0.0344 (p-value corresponds to Chi-square test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Fisher Exact · p = 1 (p-value corresponds to a Fisher's exact test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Chi-squared · p = 0.0235 (p-value corresponds to Chi-square test of the comparisons between Cenegermin and Vehicle in all patients.)
SecondaryChange From Baseline in "Quality of Life, Dry Eye Treatment Satisfaction & Bother and Dry Eye Symptom-Bother" Modules Measured by "Impact of Dry Eye on Everyday Life [IDEEL]" Questionnaire at Week 4, Week, 8, Week 12, and Week 16

IDEEL was a 57-item questionnaire that assessed the impact of dry eye symptoms on everyday life. It consisted of 3 modules: * Dry eye Quality of Life (27 items) composed by 3 dimensions: 1. Impact on Daily Activities 2. Emotional Impact 3. Impact on Work Scores for each dimension of this module ranged from 0 to 100, where higher scores indicated less impact on daily activities, on work and emotions. * Treatment Satisfaction \& Bother (8 items) composed by 2 dimensions: 1. Satisfaction with Treatment Effectiveness 2. Treatment-Related Bother / Inconvenience Scores for each dimension of this module range from 0 to 100, where higher scores indicate greater satisfaction with treatment effectiveness and less treatment-related bother. * Symptom Bother (20 items) composed by 1 dimension: 1. Dry Eye Symptom-Bother. Scores for the dimension of this module ranged from 0 to 100, where higher scores indicated greater symptom bother. No combination of dimensions scores was done.

Time frame:
At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Reported as:
Mean · score on a scale
Change From Baseline in "Quality of Life, Dry Eye Treatment Satisfaction & Bother and Dry Eye Symptom-Bother" Modules Measured by "Impact of Dry Eye on Everyday Life [IDEEL]" Questionnaire at Week 4, Week, 8, Week 12, and Week 16
score on a scaleCenegermin - FASVehicle - FAS
QoL (Impact on Daily Activities) - Week 410.9 ± 20.710.3 ± 16.4
QoL (Impact on Daily Activities) - Week 89.2 ± 20.67.2 ± 17.0
QoL (Impact on Daily Activities) - Week 1211.9 ± 20.85.6 ± 19.3
QoL (Impact on Daily Activities) - Week 1610.8 ± 19.68.1 ± 16.2
QoL (Emotional Impact due to Dry Eye) - Week 44.3 ± 21.610.1 ± 17.5
QoL (Emotional Impact due to Dry Eye) - Week 86.1 ± 20.08.5 ± 16.0
QoL (Emotional Impact due to Dry Eye) - Week 127.4 ± 21.87.4 ± 16.6
QoL (Emotional Impact due to Dry Eye) - Week 166.7 ± 25.07.6 ± 16.1
QoL (Impact on Work due to Dry Eye) - Week 49.8 ± 24.713.4 ± 16.1
QoL (Impact on Work due to Dry Eye) - Week 89.5 ± 21.78.1 ± 14.3
QoL (Impact on Work due to Dry Eye) - Week 1210.4 ± 19.911.8 ± 20.0
QoL (Impact on Work due to Dry Eye) - Week 1613.6 ± 21.38.9 ± 15.1
TS (Satisfaction with Effectiveness) - Week 411.3 ± 30.410.1 ± 25.1
TS (Satisfaction with Effectiveness) - Week 812.0 ± 25.55.2 ± 25.2
TS (Satisfaction with Effectiveness) - Week 1213.1 ± 26.87.4 ± 25.7
TS (Satisfaction with Effectiveness) - Week 1613.1 ± 29.07.9 ± 26.1
TS (Treatment Bother/Inconvenience) - Week 45.5 ± 21.76.2 ± 12.7
TS (Treatment Bother/Inconvenience) - Week 83.3 ± 18.95.0 ± 14.8
TS (Treatment Bother/Inconvenience) - Week 124.5 ± 19.84.2 ± 12.4
TS (Treatment Bother/Inconvenience) - Week 165.4 ± 18.53.3 ± 11.3
Symptom-Bother - Week 4-5.8 ± 18.7-11.9 ± 12.5
Symptom-Bother - Week 8-7.2 ± 16.4-7.9 ± 12.9
Symptom-Bother - Week 12-8.6 ± 15.5-9.5 ± 17.7
Symptom-Bother - Week 16-8.0 ± 17.0-9.2 ± 13.9
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.888 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.651 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.267 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.459 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.192 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.568 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.871 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.85 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.364 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.646 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.739 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.664 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.846 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.248 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.341 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.413 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.927 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.914 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.564 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.489 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.082 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.848 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.805 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.833 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
Other pre-specifiedNumber of Patients With at Least One Treatment-emergent Adverse Event (TEAE) From Screening Day to Week 24

Treatment emergent adverse events (TEAEs) were undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment.

Time frame:
From Screening day (Day -8) up to Week 24 (Visit 7 - Follow-up)
Reported as:
Count of participants · Participants
Number of Patients With at Least One Treatment-emergent Adverse Event (TEAE) From Screening Day to Week 24
ParticipantsCenegermin - SAFVehicle - SAF
Any TEAE2718
Any TEAE - Ophtalmic2612
Any TEAE . Non-ophtalmic99
Any severe TEAE01
Any severe TEAE - Ophtalmic01
Any severe TEAE - Non-ophtalmic00
Any serious TEAE00
Any serious TEAE - Ophtalmic00
Any serious TEAE - Non-ophtalmic00
Any non-serious TEAE2718
Any ADR2612
Any ADR - Ophtalmic2610
Any ADR - Non-ophtalmic34
Any Serious ADR00
Any Serious ADR leading to IMP discontinuation01
Any TEAE leading to study discontinuation01
Any TEAE leading to death00
Other pre-specifiedUse of Preservative Free Artificial Tears Use (Number of Drops/Day).

Use of Preservative Free Artificial Tears by Study Period is calculated as: total number of drops of the preservative free artificial tears during the X period/ total number of days of the X period \* 100.

Time frame:
Treatment period (Day 1 to Week 4), Follow-up period (Week 4 to Week 24), Overall period (Day 1 to Week 24)
Reported as:
Median · number of drops
Use of Preservative Free Artificial Tears Use (Number of Drops/Day).
number of dropsCenegermin - FASVehicle - FAS
Treatment period261.2 ± 220.2215.7 ± 184.7
Follow-up period330.0 ± 178.1317.6 ± 168.3
Overall period294.7 ± 202.5268.1 ± 182.6
Other pre-specifiedChange From Baseline in Schirmer I Test (Without Anaesthesia) at Week 2

The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.

Time frame:
At week 2 (Visit 2)
Reported as:
Mean · millimeters
Change From Baseline in Schirmer I Test (Without Anaesthesia) at Week 2
millimetersCenegermin - FASVehicle - FAS
Change From Baseline in Schirmer I Test (Without Anaesthesia) at Week 24.4 ± 5.01.0 ± 2.4
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
Other pre-specifiedChange From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 2

The NEI/Industry Workshop guidelines were used for grading the scale of corneal and conjunctival damage. The cornea was divided into five sectors (central, superior, inferior, nasal and temporal), each of which was scored on a scale of 0-3, with a maximal total corneal staining score of 15. Both nasally and temporally, the conjunctiva was divided into a superior paralimbal area, an inferior paralimbal area, and a peripheral area with a grading scale of 0-3 and with a maximal total score of 9 for the nasal and temporal conjunctiva (overall the total score ranged from 0-18). Briefly, grade 0 reflected normal/healthy situation, whereas grade 3 reflected a severe damage in the considered sector.

Time frame:
At Week 2 (Visit 2)
Reported as:
Mean · score on a scale
Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 2
score on a scaleCenegermin - FASVehicle - FAS
Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 2-2.6 ± 4.8-2.0 ± 5.2
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.046 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
Other pre-specifiedChange From Baseline in Tear Film Break-Up Time (TFBUT) at Week 2

Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological.

Time frame:
At Week 2 (Visit 2)
Reported as:
Mean · seconds
Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 2
secondsCenegermin - FASVehicle - FAS
Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 20.7 ± 2.10.2 ± 2.0
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.34 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
Other pre-specifiedChange From Baseline in Symptoms Questionnaire (SANDE) Global Scores, and for Severity and Frequency at Week 2, and Week 4

SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).

Time frame:
At Week 2 (Visit 2) and Week 4 (Visit 3)
Reported as:
Mean · score on a scale
Change From Baseline in Symptoms Questionnaire (SANDE) Global Scores, and for Severity and Frequency at Week 2, and Week 4
score on a scaleCenegermin - FASVehicle - FAS
Global Score - Change from baseline to Week 2-2.1 ± 18.0-12.3 ± 13.7
Global Score - Change from baseline to Week 4-11.5 ± 17.4-15.0 ± 18.0
Severity - Change from baseline to Week 2-0.5 ± 20.1-12.3 ± 14.9
Severity - Change from baseline to Week 4-9.2 ± 19.7-13.6 ± 17.2
Frequency - Change from baseline to Week 2-3.8 ± 18.9-12.0 ± 14.7
Frequency - Change from baseline to Week 4-14.5 ± 18.8-16.9 ± 22.2
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.017 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.339 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · t-test, 2 sided · p = 0.004 (p-value corresponds to a two sample (independent group) t-test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.292 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.09 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = 0.54 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all patients.)
Other pre-specifiedNumber of Patients Experienced a Worsening in Symptom Scores (SANDE Global Score) and/or NEI Score ≥ 50% Assessed at Week 2

Symptoms Scores (SANDE) and/or NEI Score were punctually described in the previous outcome descriptions. For Sande score, the scale ranges from 0 to 100 for both severity and frequency, where 0 was the best condition and 100 marked the worst condition. Hence the higher the score, the worse the outcome. For NEI score, the maximum score (worst outcome) was 15, and the minimum (best outcome) was 0; hence the higher the score, the worse the outcome.

Time frame:
At Week 2 (Visit 2)
Reported as:
Count of participants · Participants
Number of Patients Experienced a Worsening in Symptom Scores (SANDE Global Score) and/or NEI Score ≥ 50% Assessed at Week 2
ParticipantsCenegermin - FASVehicle - FAS
Worsening in symptom scores (SANDE global score)175
NEI score >= 50%10
Worsening in symptom scores and/or NEI score >= 50185
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Chi-squared · p = 0.0064 (p-value corresponds to Chi-square test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Fisher Exact · p = 1 (p-value corresponds to a Fisher's exact test of the comparisons between Cenegermin and Vehicle in all patients.)
  • Cenegermin - FAS vs Vehicle - FAS · Chi-squared · p = 0.0034 (p-value corresponds to Chi-square test of the comparisons between Cenegermin and Vehicle in all patients.)
Other pre-specifiedChange From Baseline in Schirmer Test II (With Topical Anaesthesia) at Week 4

Schirmer Test II (with anaesthetic) measured baseline plus reflex secretion. The Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.

Time frame:
At Week 4 (Visit 3)
Reported as:
Mean · millimeters
Change From Baseline in Schirmer Test II (With Topical Anaesthesia) at Week 4
millimetersCenegermin - FASVehicle - FAS
Change From Baseline in Schirmer Test II (With Topical Anaesthesia) at Week 44.3 ± 4.21.4 ± 3.7
Statistical analysis
  • Cenegermin - FAS vs Vehicle - FAS · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value corresponds to a non-parametric Mann-Whitney-Wilcoxon (Wilcoxon rank sum) test of the comparisons between Cenegermin and Vehicle in all participants.)
Other pre-specifiedChange From Baseline in Best Corrected Distance Visual Acuity (BCDVA)

Best corrected visual acuity (BCDVA) was determined by careful refraction according to the standard protocol for refraction. Chart 1 was used for testing the VA of the right eye; Chart 2 for the left eye; and Chart R for refraction only. Retroilluminated standard Early Treatment of Diabetic Retinopathy Study (ETDRS) charts were used. They had 5 Sloan letters on each line of equal difficulty, and there was a geometric progression in letter size from line to line. VAS awarded one point for every letter correctly guessed. A distance of 4 meters was required between the subject's eyes and the VA chart. When a subject cannot read at least 20 letters on the chart at 4 meters, the subject was tested at 1 meter. If 20 or more letters were read at 4 meters, the VAS for that eye was recorded as the number of letters correct at 4 meters plus 30. Otherwise, the VAS was the number of letters read correctly at 1 meter plus the number read at 4 meters. The higher the score the better the outcome.

Time frame:
At Week 2 (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Reported as:
Count of participants · Participants
Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA)
ParticipantsCenegermin - FASVehicle - FAS
CFB to Week 2 - No change3229
CFB to Week 2 - 20/63 to 20/4001
CFB to Week 2 - 20/50 to 20/4001
CFB to Week 2 - 20/40 to 20/2511
CFB to Week 2 - 20/32 to 20/2010
CFB to Week 2 - 20/32 to 20/2511
CFB to Week 2 - 20/25 to 20/2032
CFB to Week 2 - 20/20 to 20/1620
CFB to Week 2 - 20/20 to 20/2512
CFB to Week 2 - 20/16 to 20/12.501
CFB to Week 2 - 20/16 to 20/2010
CFB to Week 2 - 20/16 to 20/2510
CFB to Week 2 - 20/16 to 20/3201
CFB to Week 4 - No change3133
CFB to Week 4 - 20/63 to 20/4001
CFB to Week 4 - 20/40 to 20/2511
CFB to Week 4 - 20/40 to 20/3210
CFB to Week 4 - 20/32 to 20/2001
CFB to Week 4 - 20/32 to 20/2510
CFB to Week 4 - 20/25 to 20/2032
CFB to Week 4 - 20/20 to 20/2530
CFB to Week 4 - 20/20 to 20/3210
CFB to Week 4 - 20/16 to 20/2020
CFB to Week 4 - 20/16 to 20/3201
CFB to Week 8 - No change2629
CFB to Week 8 - 20/63 to 20/4001
CFB to Week 8 - 20/50 to 20/4001
CFB to Week 8 - 20/40 to 20/2001
CFB to Week 8 -20/40 to 20/2510
CFB to Week 8 -20/40 to 20/3210
CFB to Week 8 - 20/40 to 20/5010
CFB to Week 8 -20/32 to 20/2010
CFB to Week 8 -20/32 to 20/2511
CFB to Week 8 - 20/25 to 20/2021
CFB to Week 8 - 20/25 to 20/3210
CFB to Week 8 - 20/20 to 20/1621
CFB to Week 8 - 20/20 to 20/2522
CFB to Week 8 - 20/16 to 20/2020
CFB to Week 8 -20/16 to 20/3201
CFB to Week 12 - no change2930
CFB to Week 12 - 20/63 to 20/8001
CFB to Week 12 -20/50 to 20/6301
CFB to Week 12 -20/40 to 20/2001
CFB to Week 12 - 20/40 to 20/3210
CFB to Week 12 - 20/32 to 20/2010
CFB to Week 12 - 20/32 to 20/2511
CFB to Week 12 - 20/25 to 20/2031
CFB to Week 12 - 20/25 to 20/3210
CFB to Week 12 - 20/20 to 20/1601
CFB to Week 12 -20/20 to 20/2512
CFB to Week 12 - 20/20 to 20/3210
CFB to Week 12 -20/16 to 20/2010
CFB to Week 12 -20/16 to 20/5001
CFB to Week 12 - 20/12.5 to 20/1610
CFB to Week 16 - no change2527
CFB to Week 16 -20/63 to 20/5001
CFB to Week 16 -20/50 to 20/4001
CFB to Week 16 - 20/40 to 20/2001
CFB to Week 16 -20/40 to 20/2510
CFB to Week 16 -20/40 to 20/3210
CFB to Week 16 - 20/40 to 20/5010
CFB to Week 16 -20/32 to 20/2522
CFB to Week 16 -20/25 to 20/1601
CFB to Week 16 -20/25 to 20/2040
CFB to Week 16 -20/25 to 20/3202
CFB to Week 16 -20/20 to 20/1630
CFB to Week 16 -20/20 to 20/2522
CFB to Week 16 -20/16 to 20/2021

Adverse events

Collected over AEs were collected from the screening visit (Day -8) until last Follow-Up visit (Week 24).. Non-serious events are listed at a 4.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cenegermin - SAF0/44 (0%)0/44 (0%)27/44 (61.4%)
Vehicle - SAF0/40 (0%)0/40 (0%)18/40 (45%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCenegermin - SAFVehicle - SAF
Eye painEye disorders21/444/40
Eyelid painEye disorders7/440/40
HeadacheNervous system disorders3/444/40
Dry eyeEye disorders0/443/40
Eye dischargeEye disorders2/442/40
Foreign body sensation in eyesEye disorders0/442/40
Vision blurredEye disorders1/442/40
Conjunctival hyperaemiaEye disorders2/441/40
Eye irritationEye disorders2/441/40
PhotophobiaEye disorders2/440/40

Baseline characteristics

Full Analysis set (FAS): The FAS population consisted of all randomized patients who received at least one dose of the tnvestigational product. FAS population was analysed according to intention-to-treat (ITT) principle, i.e., by treatment allocation regardless happening of intercurrent events (treatment policy strategy). The FAS population was used for the primary analysis of the study and to present results on efficacy data.

Age, Categorical
Age, Categorical(Participants)Cenegermin - FASVehicle - FASTotal
<=18 years000
Between 18 and 65 years352762
>=65 years91322
Age, Continuous
Age, Continuous(years)Cenegermin - FASVehicle - FASTotal
Mean55.0 ± 13.9358.1 ± 12.8456.5 ± 13.43
Sex: Female, Male
Sex: Female, Male(Participants)Cenegermin - FASVehicle - FASTotal
Female383573
Male6511
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cenegermin - FASVehicle - FASTotal
Hispanic or Latino325
Not Hispanic or Latino413879
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cenegermin - FASVehicle - FASTotal
American Indian or Alaska Native000
Asian044
Native Hawaiian or Other Pacific Islander000
Black or African American448
White373067
More than one race000
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(participants)Cenegermin - FASVehicle - FASTotal
United States212142
Italy231942
08

Study locations

10 sites
  • Lugene Eye Institute - Glendale Office
    Glendale, California 91204, United States
  • The Johns Hopkins University
    Baltimore, Maryland 21218, United States
  • Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • OCLI (Ophthalmic Consultants of Long Island)
    Garden City, New York 11530, United States
  • Scheie Eye Institute
    Philadelphia, Pennsylvania 19104, United States
  • Houston Eye Associates HEA - Gramercy Location
    Houston, Tennessee 77025, United States
  • Toyos Clinic - Nashville
    Nashville, Tennessee 37215, United States
  • AOU Gaspare Rodolico - Ospedale San Marco
    Catania, 95123, Italy
  • Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica
    Milan, 20123, Italy
  • AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica
    Roma, 00161, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in May 2023, 15 months.

Results were first posted in Dec 2024, 1 year 6 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Nov 29, 2021
StartActual
Jan 27, 2022
Primary completionActual
May 24, 2023
CompletionActual
May 24, 2023
Results first posted
Dec 4, 2024
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05136170
Responsible party
Sponsor
First posted
Nov 29, 2021
Start date
Jan 27, 2022
Primary completion
May 24, 2023
Completion
May 24, 2023
Results posted
Dec 4, 2024
Last update
Nov 26, 2025

Study contacts

Flavio Mantelli, MD
study director · Dompé Farmaceutici

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenegermin

Start the discussion